SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress

Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis

Global Blood Therapeutics Announces Pricing of Initial Public Offering

Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update Blueprint Medicines

Editas Medicine Raises $120 Million to Advance Genome Editing

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

bluebird bio Reports Second Quarter 2015 Financial Results and Recent Operational Progress

SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015

bluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference

Zafgen to Present at Canaccord Genuity 35th Annual Growth Conference 2015

Blueprint Medicines to Present at 2015 Wedbush PacGrow Healthcare Conference

Zafgen to Host Conference Call to Discuss Second Quarter 2015 Financial Results

Foundation Medicine to Present at Wedbush PacGrow Healthcare Conference

Eleven Biotherapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015

Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria

CytomX Announces Management Team Promotions

Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015

Foundation Medicine Announces 2015 Second Quarter Results and Recent Highlights

Foundation Medicine Initiates Multi-Center Clinical Study Evaluating Its Circulating Tumor DNA (ctDNA) Assay in Multiple Tumor Types

Alcresta Appoints Russell Clayton, D.O., Chief Medical Officer

Voyager Therapeutics Appoints Michael Higgins to Board of Directors

Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates

Afferent Pharmaceuticals Raises $55 Million in Oversubscribed Crossover Financing

Foundation Medicine Announces Timing for Second Quarter 2015 Financial Results and Conference Call

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

Voyager Therapeutics Appoints Perry A. Karsen to Board of Directors

Blueprint Medicines Added to Russell 2000®, 3000® and Global Indexes

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Eleven Biotherapeutics Announces Executive Change

Agios Appoints Maykin Ho, Ph.D., to its Board of Directors

Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate

DC Devices Completes Enrollment In Clinical Trial of the First Transcatheter Device to Treat Diastolic Heart Failure; Announces Name Change to Corvia Medical

IMS Health and Foundation Medicine Announce Collaboration to Optimize Targeting of Precision Therapies in Oncology

Zafgen to Present at JMP Securities Life Sciences Conference 2015

CytomX Raises $70 Million in Series D Financing

Philip Gregory, D. Phil., Joins bluebird bio as Chief Scientific Officer

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Blueprint Medicines Reports First Quarter 2015 Financial Results

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

Zafgen to Present at 2015 BIO International Convention

bluebird bio Completes NIH RAC Review of HGB-208 Pediatric Study Protocol

SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression

Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide (RM-493) in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies

Celgene and bluebird bio to Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA